Viking Therapeutics (VKTX) Other financing activities (2015 - 2026)
Viking Therapeutics (VKTX) posted Other financing activities of $1.0 million for Q2 2026, up 100.0% sequentially from $500000.0 in Q1 2026, and up 81.49% YoY from $551000.0 in Q2 2025.
Viking Therapeutics (VKTX) Other financing activities (2015 - 2026) Analysis & Trends
Viking Therapeutics has reported Other financing activities for 6 years, with the latest figure at $1.0 million in Q2 2026.
- Quarterly Other financing activities rose 81.49% year-over-year to $1.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.6 million (down 35.0% YoY) and the FY2025 annual result came in at $2.0 million, down 80.77% from the prior year.
- Other financing activities improved to $1.0 million in Q2 2026 per VKTX's latest filing, from $500000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $4.4 million in Q1 2024 and troughed at -$200000.0 in Q4 2023.
- A 4-year average of $1.6 million and a median of $664000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2024 and 2025: Other financing activities surged 393.5% in 2024, then tumbled 92.0% in 2025.
- Over 4 years, Other financing activities stood at -$200000.0 in 2023, then soared by 393.5% to $587000.0 in 2024, then increased by 13.12% to $664000.0 in 2025, then jumped by 50.6% to $1.0 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $1.0 million, $500000.0, and $664000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Dec 31, 2025 | 664,000.00 |
| Sep 30, 2025 | 436,000.00 |
| Sep 30, 2025 | 436,000.00 |
| Jun 30, 2025 | 551,000.00 |
| Jun 30, 2025 | 551,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Dec 31, 2024 | 587,000.00 |
| Dec 31, 2024 | 587,000.00 |
| Sep 30, 2024 | 2.51 Mn |
| Sep 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 4.36 Mn |
| Mar 31, 2024 | 4.36 Mn |